The Use of Mesenchymal Stem Cells and their Derived Extracellular Vesicles in Cardiovascular Disease Treatment

Abstract

BACKGROUND: Cardiovascular disease (CVD), including disorders of cardiac muscle and vascular, is the first cause of death globally. Many unsuccessful attempts have been made to intervene in the disease's pathogenesis and treat it. Stem cell-based therapies as a regeneration strategy cast a new hope for CVD treatment. One of the most well-known stem cells is mesenchymal stem cells (MSCs), classified as one of the adult stem cells and can be obtained from different tissues. These cells have superior properties, such as proliferation and highly specialized differentiation. On the other hand, they have the potential to modulate the immune system and anti-inflammatory activity. One of their most important features is the secreting the extracellular vesicles (EVs) like exosomes (EXOs) as an intercellular communication system mediating the different physiological and pathophysiological affairs. METHODS: In this review study, the importance of MSC and its secretory exosomes for the treatment of heart disease has been together and specifically addressed and the use of these promising natural and accessible agents is predicted to replace the current treatment modalities even faster than we imagine. RESULTS: MSC derived EXOs by providing a pro-regenerative condition allowing innate stem cells to repair damaged tissues successfully. As a result, MSCs are considered as the appropriate cellular source in regenerative medicine. In the plethora of experiments, MSCs and MSC-EXOs have been used for the treatment and regeneration of heart diseases and myocardial lesions. CONCLUSIONS: Administration of MSCs has been provided a replacement therapeutic option for heart regeneration, obtaining great attention among the basic researcher and the medical doctors.

The Mystery of Red Blood Cells Extracellular Vesicles in Sleep Apnea with Metabolic Dysfunction

“…As such, exosomes can provide protection of RNA content from degradation in the environment, enabling a stable source for reliable detection of RNA biomarkers [ 119 , 123 ]. EVs have emerged as an important drug delivery system to deliver therapeutic agents, including proteins and gene therapy for the treatment of many diseases such as CVD [ 267 , 268 , 269 ]. For clinical applications, future efforts will be focused on the manufacturing process, characterization of EVs, and EVs-associated safety issues.…”

Exosomes of Mesenchymal Stem Cells as a Proper Vehicle for Transfecting miR-145 into the Breast Cancer Cell Line and Its Effect on Metastasis

“…Exosomes are small vesicles (30-150 nm) with a bilayer lipid membrane and an endocytic origin that have received increasing attention in recent years for their association with biological and pathophysiological processes [ 4 , 5 ]. Several investigations exhibited that due to their small size, exosomes may be utilized as delivery vehicles for tumor therapy without toxicity or immunogenicity risk associated with artificial carriers such as liposomes or nanoparticles.…”

FO‐SPR biosensor calibrated with recombinant extracellular vesicles enables specific and sensitive detection directly in complex matrices

“…EVs actively travel in intercellular matrices, eventually reaching the circulation, and potentially provide a minimally invasive route to access disease specific proteomic and genomic biomarkers (Raghu et al., 2018). In this context, analysis of EVs has drawn huge attention lately for diagnosis, prognosis and therapy of different diseases, such as diabetes (Pardo et al., 2018; Xing et al., 2020), obesity (Pardo et al., 2018), neurodegenerative diseases (Croese & Furlan, 2018), cardiovascular diseases (Khoei et al., 2020) and cancer (Bebelman et al., 2018; Wendler et al., 2017; Xu et al., 2018). However, there are multiple aspects that often introduce an extra level of complexity in studying, characterizing and finally understanding the full potential of EVs, such as: (1) the existence of numerous methods for separating and characterizing EVs, (2) the intrinsic heterogeneity of EV subtypes with varying size (from 40 to >500 nm), molecular patterns, and origin, and (3) the complexity of biofluids (Tkach et al., 2017; Tulkens et al., 2020; Van Deun et al., 2017).…”